Elanco Animal Health Incorporated (ELAN) Research

Elanco Animal Health, a firm dedicated to animal well-being, creates, produces, and commercializes a diverse array of solutions for both companion animals and livestock. For household pets, the company provides preventative health solutions, including parasiticides and vaccinations, designed to guard against common ailments like worms, fleas, and ticks, with notable brands such as Seresto, Advantage, Advantix, and Advocate. Additionally, Elanco supplies therapeutic treatments for canine and feline conditions including pain, osteoarthritis, ear infections, cardiovascular issues, and dermatological problems, marketed under labels like Galliprant and Claro. Its portfolio for agricultural animals encompasses vaccines, antibiotics, parasiticides, and other essential products for poultry and aquaculture farming. This segment also features nutritional supplements such as enzymes, probiotics, and prebiotics to support animal health and growth. Furthermore, the company offers a comprehensive suite of products for ruminant and swine operations, comprising vaccines, antibiotics, implants, and parasiticides, often recognized by brands like Rumensin and Baytril. Elanco distributes its offerings through various channels, including independent distributors, veterinary clinics, and a broad spectrum of farm animal producers, from cattle and dairy farms to pig, poultry, and aquaculture enterprises. Established in 1954, Elanco Animal Health Incorporated maintains its corporate headquarters in Greenfield, Indiana.

Market snapshot

Symbol
ELAN
Price
$24.22
Day change
+3.55%
Market cap
$12.1B
P/E ratio
-49.81x
52-week range
13.16-27.72
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Next earnings
in 2 months
Analyst price target
$28.40

Recent news

  • Jim Cramer Says He Feels 'Something Not Well' At Zoetis, Names A Rival As His Pick

    On CNBC's “Mad Money Lightning Round,” Jim Cramer said about Zoetis Inc (NYSE:ZTS) that he feels "something not well there."

  • Elanco Animal Health Moves Higher On Earnings Strength And Product Momentum

    Shares of Elanco Animal Health Incorporated (NYSE:ELAN) are trading higher on Wednesday, following a recent announcement regarding the approval of its products, Negasunt Powder and Tanidil, which received emergency use authorization.

Peer companies

  • Align Technology, Inc. (ALGN)
  • Encompass Health Corporation (EHC)
  • The Ensign Group, Inc. (ENSG)
  • Neurocrine Biosciences, Inc. (NBIX)
  • Qiagen N.V. (QGEN)
  • Dr. Reddy's Laboratories Limited (RDY)
  • Revolution Medicines, Inc. (RVMD)
  • Revvity, Inc. (RVTY)

Recent insider activity

  • VanHimbergen Robert M — A-Award (8.1514 shares) on 2026-06-12
  • Simmons Jeffrey N — A-Award (116.9603 shares) on 2026-06-12
  • Modi Rajeev A. — A-Award (61.1059 shares) on 2026-06-12
  • VanHimbergen Robert M — A-Award (8.2608 shares) on 2026-05-29
  • Modi Rajeev A. — A-Award (61.9258 shares) on 2026-05-29

Open Elanco Animal Health Incorporated (ELAN) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.